Incidence of Atrial Fibrillation and Mineralocorticoid Receptor Activity in Patients With Medically and Surgically Treated Primary Aldosteronism

被引:168
|
作者
Hundemer, Gregory L. [1 ,2 ,3 ]
Curhan, Gary C. [1 ,2 ,3 ,4 ]
Yozamp, Nicholas [2 ,3 ]
Wang, Molin [2 ,3 ,4 ]
Vaidya, Anand [2 ,3 ,5 ]
机构
[1] Brigham & Womens Hosp, Dept Med, Div Renal Med, 75 Francis St, Boston, MA 02115 USA
[2] Harvard Med Sch, Boston, MA USA
[3] Brigham & Womens Hosp, Dept Med, 75 Francis St, Boston, MA 02115 USA
[4] Harvard TH Chan Sch Publ Hlth, Dept Epidemiol, Dept Biostat, Boston, MA USA
[5] Brigham & Womens Hosp, Dept Med, Div Endocrinol Diabet & Hypertens, Ctr Adrenal Disorders, 75 Francis St, Boston, MA 02115 USA
基金
美国国家卫生研究院;
关键词
ARTERIAL-HYPERTENSION; HYPERALDOSTERONISM; EPLERENONE;
D O I
10.1001/jamacardio.2018.2003
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
IMPORTANCE Primary aldosteronism (PA) is an ideal condition to evaluate the role of the mineralocorticoid receptor (MR) in the pathogenesis of atrial fibrillation (AF). OBJECTIVE To investigate whether MR antagonist therapy or surgical adrenalectomy in PA influence the risk for incident AF. DESIGN This cohort study included patients aged 18 years and older. Patients with PA and age-matched patients with essential hypertension were identified via electronic health records. Patients with a history of AF, myocardial infarction, congestive heart failure, or stroke were excluded. Data were collected between 1991 and the end of 2016 in an academic medical center, with a mean follow-up duration of approximately 8 years. EXPOSURES Patients with PA treated with MR antagonists or surgical adrenalectomy were compared with patients with essential hypertension. Patients with PA who were treated with MR antagonists were categorized by whether their plasma renin activity remained suppressed (< 1 ng/mL/h) or substantially increased (>= 1 ng/mL/h), as proxies for insufficient or sufficient MR blockade. MAIN OUTCOMES AND MEASURE Incident AF. RESULTS A total of 195 patients with PA who were treated with MR antagonists and 201 patients with PA treated with surgical adrenalectomy were included, as well as 40 092 age-matched patients with essential hypertension. Despite similar blood pressure at study entry and throughout follow-up, patients with PA who were treated with MR antagonists whose renin remained suppressed had a higher risk for incident AF than patients with essential hypertension (adjusted HR, 2.55 [95% CI, 1.75-3.71]). They also had an adjusted 10-year cumulative AF incidence difference of 14.1(95% CI, 6.7-21.5) excess cases per 100 persons compared with patients with essential hypertension. In contrast, patients with PA who were treated with MR antagonists and whose renin increased and patients with PA who were treated with surgical adrenalectomy had no statistically significant difference in risk for incident AF compared with patients with essential hypertension. CONCLUSIONS AND RELEVANCE When compared with patients with essential hypertension, patients with PA treated with MR antagonists such that renin remained suppressed (as a proxy for insufficient MR blockade) had a significantly higher risk for incident AF; however, treatment of PA with MR antagonists to substantially increase renin (suggesting sufficient MR blockade), or with surgical adrenalectomy (to remove the source of aldosteronism), was associated with no significant difference in risk for developing AF. These findings add to the growing body of evidence suggesting that MR blockade may be a potential therapy to decrease the incidence of AF.
引用
收藏
页码:768 / 774
页数:7
相关论文
共 50 条
  • [21] Salt intake in mineralocorticoid receptor antagonist-treated primary aldosteronism: foe or ally?
    Fountoulakis, Stelios
    Papanastasiou, Labrini
    Voulgaris, Nikos
    Kounadi, Theodora
    Markou, Athina
    Chrousos, George P.
    Piaditis, George
    HORMONES-INTERNATIONAL JOURNAL OF ENDOCRINOLOGY AND METABOLISM, 2020, 19 (02): : 223 - 232
  • [22] ROLE OF ATRIAL-NATRIURETIC-PEPTIDE IN MINERALOCORTICOID ESCAPE PHENOMENON IN PATIENTS WITH PRIMARY ALDOSTERONISM
    NAKAMURA, T
    ICHIKAWA, S
    SAKAMAKI, T
    SATO, K
    KOGURE, M
    TAJIMA, Y
    KATO, T
    MURATA, K
    PROCEEDINGS OF THE SOCIETY FOR EXPERIMENTAL BIOLOGY AND MEDICINE, 1987, 185 (04): : 448 - 454
  • [23] Mineralocorticoid Receptor Antagonist Effect on Aldosterone to Renin Ratio in Patients With Primary Aldosteronism
    Pecori, Alessio
    Buffolo, Fabrizio
    Burrello, Jacopo
    Mengozzi, Giulio
    Rumbolo, Francesca
    Avataneo, Valeria
    D'Avolio, Antonio
    Rabbia, Franco
    Bertello, Chiara
    Veglio, Franco
    Mulatero, Paolo
    Monticone, Silvia
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2021, 106 (09): : E3655 - E3664
  • [24] EFFECTS OF MINERALOCORTICOID RECEPTOR ANTAGONISTS ON ALDOSTERONE TO RENIN RATIO IN PATIENTS WITH PRIMARY ALDOSTERONISM
    Pecori, Alessio
    Buffolo, Fabrizio
    Burrello, Jacopo
    Mengozzi, Giulio
    Rumbolo, Francesca
    Avataneo, Valeria
    D'Avolio, Antonio
    Rabbia, Franco
    Bertello, Chiara
    Veglio, Franco
    Mulatero, Paolo
    Monticone, Silvia
    JOURNAL OF HYPERTENSION, 2022, 40 (SUPPL 1) : E200 - E201
  • [25] Atrial fibrillation is an independent predictor of cardiovascular events in patients with primary aldosteronism
    Sakaguchi, S.
    Okamoto, R.
    Inoue, C.
    Kamemura, K.
    Kurihara, I.
    Takeda, Y.
    Ohno, Y.
    Rakugi, H.
    Katabami, T.
    Tanabe, A.
    Tamura, K.
    Yamamoto, K.
    Yano, Y.
    Dohi, K.
    Naruse, M.
    EUROPEAN HEART JOURNAL, 2021, 42 : 2316 - 2316
  • [26] Primary Aldosteronism More Prevalent in Patients With Cardioembolic Stroke and Atrial Fibrillation
    Nguyen, Van
    Tu, Tian Ming
    Mamauag, Marlie Jane B.
    Lai, Jovan
    Saffari, Seyed Ehsan
    Aw, Tar Choon
    Ong, Lizhen
    Foo, Roger S. Y.
    Chai, Siang Chew
    Fones, Shaun
    Zhang, Meifen
    Puar, Troy H.
    FRONTIERS IN ENDOCRINOLOGY, 2022, 13
  • [27] Cardiovascular events and all-cause mortality in surgically or medically treated primary aldosteronism: A Meta-analysis
    Jing, Ying
    Liao, Kangla
    Li, Ruolin
    Yang, Shumin
    Song, Ying
    He, Wenwen
    Wang, Kanran
    Yang, Jun
    Li, Qifu
    Hu, Jinbo
    JOURNAL OF THE RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM, 2021, 22 (01)
  • [28] Mineralocorticoid receptor antagonists and prevention of atrial fibrillation in patients with hypertension Reply
    Mujovic, Nebojsa
    Marinkovic, Milan
    Mihajlovic, Miroslav
    Mujovic, Natasa
    Potpara, Tatjana S.
    KARDIOLOGIA POLSKA, 2020, 78 (06) : 610 - 611
  • [29] Can Patients with Heart Failure and Atrial Fibrillation be treated medically or with Ablation?
    Dovjak, P.
    ZEITSCHRIFT FUR GERONTOLOGIE UND GERIATRIE, 2018, 51 (03): : 366 - 366
  • [30] High incidence of atrial fibrillation in patients treated with ibrutinib
    Baptiste, Florian
    Cautela, Jennifer
    Ancedy, Yan
    Resseguier, Noemie
    Aurran, Therese
    Farnault, Laure
    Escudier, Marion
    Ammar, Chloe
    Gaubert, Melanie
    Dolladille, Charles
    Barraud, Jeremie
    Peyrol, Michael
    Cohen, Ariel
    Paganelli, Franck
    Alexandre, Joachim
    Ederhy, Stephane
    Thuny, Franck
    OPEN HEART, 2019, 6 (01):